Agilent Technologies Inc (A)vsMyriad Genetics Inc (MYGN)
A
Agilent Technologies Inc
$135.44
-2.12%
HEALTHCARE · Cap: $36.67B
MYGN
Myriad Genetics Inc
$4.69
+6.59%
HEALTHCARE · Cap: $414.63M
Smart Verdict
WallStSmart Research — data-driven comparison
Agilent Technologies Inc generates 1198% more annual revenue ($7.23B vs $557.00M). A leads profitability with a 19.6% profit margin vs -41.3%. MYGN appears more attractively valued with a PEG of 1.24. A earns a higher WallStSmart Score of 71/100 (B).
A
Strong Buy71
out of 100
Grade: B
MYGN
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.0%
Fair Value
$74.53
Current Price
$135.44
$60.91 premium
Margin of Safety
+89.7%
Fair Value
$46.95
Current Price
$4.69
$42.26 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 60.0% YoY
Strong operational efficiency at 23.7%
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Grey zone — moderate risk
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -118.5% — below average capital efficiency
Revenue declined 20.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : A
The strongest argument for A centers on EPS Growth, Operating Margin. Profitability is solid with margins at 19.6% and operating margin at 23.7%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : MYGN
The strongest argument for MYGN centers on Price/Book. PEG of 1.24 suggests the stock is reasonably priced for its growth.
Bear Case : A
The primary concerns for A are P/E Ratio, Altman Z-Score, Piotroski F-Score.
Bear Case : MYGN
The primary concerns for MYGN are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
A profiles as a mature stock while MYGN is a turnaround play — different risk/reward profiles.
MYGN carries more volatility with a beta of 1.64 — expect wider price swings.
A is growing revenue faster at 10.0% — sustainability is the question.
A generates stronger free cash flow (184M), providing more financial flexibility.
Bottom Line
A scores higher overall (71/100 vs 44/100), backed by strong 19.6% margins. MYGN offers better value entry with a 89.7% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Agilent Technologies Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.
Myriad Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?